

**Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study**

Journal:	<i>International Journal of Epidemiology</i>
Manuscript ID	IJE-2017-05-0516
Manuscript Type:	Original Article
Date Submitted by the Author:	04-May-2017
Complete List of Authors:	<p>Ong, Jue Sheng; QIMR Berghofer Medical Research Institute, Statistical Genetics  Hwang, Liang-Dar; QIMR Berghofer Medical Research Institute, Genetics and Computational Biology Department  Cuellar-Partida, Gabriel; University of Queensland Diamantina Institute for Cancer Immunology and Metabolic Medicine, Genomic Medicine; QIMR Berghofer Medical Research Institute,  Bryne, Enda; University of Queensland Institute for Molecular Bioscience  Fasching, Peter; University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, ; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg,  Hein, Alexander; Universitätsklinikum Erlangen, Department of Gynecology and Obstetrics  Burghaus, Stefanie; Universitätsklinikum Erlangen, Department of Gynecology and Obstetrics  Beckmann, Matthias; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg,  Lambrechts, Diether; Vesalius Research Center, VIB,  Van Nieuwenhuysen, Els; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven,  Vergote, Ignace; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven,  Vanderstichele, Adriaan; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven  Swerdlow, Anthony; Institute of Cancer Research, Section of Epidemiology  Jones, Michael; Institute of Cancer Research, Section of Epidemiology  Orr, Nicholas; Institute of Cancer Research  Schoemaker, Minouk; Institute of Cancer Research, Section of Epidemiology  Velez Edwards, Digna; Vanderbilt Epidemiology Center  Brenton, James; Cancer Research UK Cambridge Research Institute  Benítez, Javier; Centro Nacional de Investigaciones Oncológicas, Human</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	<p>Cancer Genetics group  García, María J. ; Centro Nacional de Investigaciones Oncologicas, Human  Cancer Genetics group  Rodríguez-Antona, Cristina; Centro Nacional de Investigaciones  Oncologicas, Hereditary Endocrine Cancer group  Rossing, Mary Anne; Program in Epidemiology, Division of Public Health  Sciences, Fred Hutchinson Cancer Research Center,  Fortner, Renée T.; Deutsches Krebsforschungszentrum, Department of  Cancer Epidemiology  Riboli, Elio; Imperial College,  Chang-Claude, Jenny; German Cancer Research Center (DKFZ), Division of  Cancer Epidemiology  Eilber, Ursula; German Cancer Research Center (DKFZ), Division of Cancer  Epidemiology  Rudolph, Anja; Deutsches Krebsforschungszentrum, Division of Cancer  Epidemiology  Wang-Gohrke, Shan; University of Ulm,  Yannoukakos, Drakoulis; National Centre for Scientific Research-  Demokritos  Goodman, Marc; Cancer Prevention and Control, Samuel Oschin  Comprehensive Cancer Institute, Cedars-Sinai Medical Center,  Antonenkova, Natalia; N.N. Alexandrov National Cancer Centre of Belarus  Dörk, Thilo; Clinics of Obstetrics and Gynaecology, Hannover Medical  School,  Dürst, Matthias; Jena-University Hospital-Friedrich Schiller University,  Department of Gynecology  Hillemanns, Peter; Clinics of Obstetrics and Gynaecology, Hannover Medical  School,  Butzow, Ralf; Department of Pathology, University of Helsinki and Helsinki  University Hospital,  Leminen, Arto; Department of Obstetrics and Gynecology, University of  Helsinki and Helsinki University Hospital,  Nevanlinna, Heli; Department of Obstetrics and Gynecology, University of  Helsinki and Helsinki University Hospital,  Pelttari, Liisa; Department of Obstetrics and Gynecology, University of  Helsinki and Helsinki University Hospital,  Edwards, Robert; Division of Gynecologic Oncology, Department of  Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh  School of Medicine, ; Ovarian Cancer Center of Excellence, Women's  Cancer Research Program, Magee-Women's Research Institute and  University of Pittsburgh Cancer Institute,  Kelley, Joseph; Division of Gynecologic Oncology, Department of  Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh  School of Medicine,  Modugno, Francesmary; Division of Gynecologic Oncology, Department of  Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh  School of Medicine,  Moysich, Kirsten; Roswell Park Cancer Institute,  Ness, Roberta; University of Texas School of Public Health,  Cannioto, Rikki; Roswell Park Cancer Institute Department of Cancer  Prevention and Population Sciences  Heitz, Florian; Department of Gynecology and Gynecologic Oncology,  Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/ Knappschaft GmbH,  Karlán, Beth; Women's Cancer Program at the Samuel Oschin  Comprehensive Cancer Institute, Cedars-Sinai Medical Center,  Olsson, Håkan; Lund university, Department of Clinical Sciences in Malmö  Kjær, Susanne; Inst. of Cancer epidemiology, Virus, Hormones and Cancer  Jensen, Allan; Danish Cancer Society, Institute of Cancer Epidemiology  Giles, Graham; Cancer Council Victoria, Cancer Epidemiology Centre  Bruinsma, Fiona; Cancer Epidemiology Centre, Cancer Council Victoria,  Hildebrandt, Michelle; The University of Texas MD Anderson Cancer Center,</p>
--	---

## Epidemiology

Liang, Dong; College of Pharmacy and Health Sciences, Texas Southern University,

Wu, X; The University of Texas, Department of Epidemiology

LeMarchand, Loic; University of Hawaii Cancer Center,

Setiawan, Veronica; University of Southern California, Preventive Medicine

Permuth, Jennifer B.; H Lee Moffitt Cancer Center and Research Institute,

Department of Cancer Epidemiology

Bisogna, Maria; Gynecology Service, Department of Surgery, Memorial

Sloan Kettering Cancer Center,

Dao, Fanny; Memorial Sloan-Kettering Cancer Center, Department of Surgery

Levine, Douglas A.; Memorial Sloan-Kettering Cancer Center, Department of Surgery

Cramer, Daniel; Harvard University,

Terry, Kathryn; Brigham and Women's Hospital, Obstetrics and Gynecology

Epidemiology Center

TwoRoger, Shelley; Harvard Medical School and Brigham and Women's

Hospital, Channing Division of Network Medicine; Harvard School of Public

Health, Department of Epidemiology

Stampfer, Meir; Harvard School of Public Health, Epidemiology

Willet, W; Harvard University T H Chan School of Public Health

Winham, Stacey; Department of Health Science Research, Division of

Biomedical Statistics and Informatics, Mayo Clinic,

Bjorge, Line; Haukeland Universitetssjukehus, Department of Gynecology and Obstetrics

Kopperud, Reidun K. ; Department of Gynecology and Obstetrics,

Haukeland University Hospital

Bischof, Katharina; Department of Gynecology and Obstetrics, Haukeland

University Hospital

Kiemeney, Lambertus; Radboud University Medical Center, Radboud

Institute for Health Sciences,

Massuger, Leon; Radboud University Medical Center, Radboud Institute for

Molecular Life Sciences, Department of Gynaecology,

Pejovic, Tanja; Department of Obstetrics & Gynecology, Oregon Health &

Science University, ; Knight Cancer Institute, Oregon Health & Science

University,

Brooks-Wilson, Angela; Canada's Michael Smith Genome Sciences Centre,

BC Cancer Agency, ; Department of Biomedical Physiology and Kinesiology,

Simon Fraser University,

Olson, Sara; Memorial Sloan-Kettering Cancer Center,

McGuire, Valerie; Stanford University,

Rothstein, Joseph; Department of Health Research and Policy -

Epidemiology, Stanford University School of Medicine,

Sieh, Weiva; Icahn School of Medicine at Mount Sinai, Department of

Genetics and Genomic Sciences

Whittemore, A; <none>,

Cook, L; University of New Mexico,

Le, Nhu; BC Cancer Agency, Cancer Control Research

Gilks, C. Blake ; University of British Columbia, Pathology and Laboratory Medicine

Gronwald, Jacek; International Hereditary Cancer Center, Department of

Genetics and Pathology, Pomeranian Medical University,

Jakubowska, Anna; International Hereditary Cancer Center, Department of

Genetics and Pathology, Pomeranian Medical University

Lubiński, Jan; International Hereditary Cancer Center, Department of

Genetics and Pathology, Pomeranian Medical University,

Kluz, Tomasz; Uniwersytet Rzeszowski, Institute of Midwifery and


Emergency Medicine

Wentzensen, Nicolas; Division of Cancer Epidemiology and Genetics,

National Cancer Institute,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	<p>Risch, HA; &lt;none&gt;, Goode, Ellen; Mayo Clinic College of Medicine, Schildkraut, Joellen; Duke Cancer Institute, Cancer Prevention, Detection &amp; Control Research Program</p> <p>Pearce, Celeste Leigh; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center,</p> <p>Berchuck, Andrew; Duke University, Pharoah, Paul; Cancer Research UK, Department of Oncology, Cambridge University, Cambridge, United Kingdom,</p> <p>Martin, Nicholas; QIMR Berghofer Department of Genetics and Computational Biology</p> <p>Chenevix-Trench, Georgia; Cancer Genetics Group, QIMR Berghofer Medical Research Institute,</p> <p>Quinn, Michael; QIMR Berghofer Department of Genetics and Computational Biology</p> <p>Cornelis, Marilyn; Northwestern University Feinberg School of Medicine, Preventive Medicine</p> <p>Gharahkhani, Puya; QIMR Berghofer Medical Research Institute, Statistical Genetics</p> <p>Webb, Penelope M.; QIMR Berghofer Medical Research Institute, Population Health</p> <p>MacGregor, Stuart; QIMR Berghofer Medical Research Institute, Statistical Genetics</p>
Key Words:	Mendelian randomization, coffee, ovarian cancer, causality, instrumental variable



## Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study

Jue-Sheng Ong, Liang-Dar Hwang, Gabriel Cuellar-Partida, (*more OCAC authors here*), Nicholas G. Martin, Georgia Chenevix-Trench, Michael C. J. Quinn, Marilyn C. Cornelis, Puya Gharahkhani, Penelope M. Webb, Stuart MacGregor

[Please refer to the attached author list document for the complete list of authors and affiliations.]

**Number of Words (main text): 3 250 words**

### Abstract:

#### Background:

Coffee consumption has been shown to be associated with various health outcomes in observational studies. However, evidence for its association with epithelial ovarian cancer (EOC) is inconsistent and it is unclear whether these associations are causal.

#### Methods:

We used SNPs associated with (i) coffee and (ii) caffeine consumption to perform Mendelian randomisation on EOC risk. We conducted a two-sample MR using genetic data on 44,062 individuals of European ancestry from the Ovarian Cancer Association Consortium (OCAC) and combined instrumental variable estimates using a Wald-type ratio estimator.

#### Results:

For all EOC cases the causal odds ratio (COR) for genetically predicted consumption of one additional cup of coffee per day was 0.92 (95% confidence interval: 0.79, 1.06). The COR was 0.90 (95% CI: 0.73, 1.10) for high-grade serous EOC. The COR for genetically predicted consumption of an additional 80 mg caffeine was 1.01 (95% CI: 0.92, 1.11) for all EOC cases and 0.90 (95% CI: 0.73, 1.10) for high-grade serous.

#### Conclusion:

1  
2  
3 We found no evidence indicative of a strong association between EOC risk and genetically predicted  
4  
5 coffee or caffeine levels. However, our estimates were not statistically inconsistent with earlier  
6  
7 observational studies and we were unable to rule out small protective associations.  
8  
9

#### 10 11 Key Message

- 12 ➤ Evidence for association between coffee and ovarian cancer is inconsistent and it is  
13 unclear whether the relationship is causal
- 14 ➤ Results from this study indicate no evidence for a strong causal association between  
15 coffee intake and ovarian cancer susceptibility.
- 16 ➤ A subsequent analysis on caffeine intake also found no causal link between caffeine  
17 intake and ovarian cancer.
- 18 ➤ The Mendelian randomization estimates were consistent to observational finding of  
19 non-causality, but are unable to rule out small protective effects.  
20  
21  
22  
23

#### 24 25 26 27 28 **Introduction:**

29  
30  
31 Coffee is one of the most consumed beverages globally. A conventional cup of coffee can contain up  
32  
33 to 1,000 types of bioactive compounds including various kinds of antioxidants, aromatic compounds  
34  
35 and most importantly, caffeine. Caffeine has been found to suppress tumour growth in various  
36  
37 animal models(1, 2), making it a potentially relevant therapeutic agent in cancer studies. Other  
38  
39 compounds present in coffee are also found to have anti-inflammatory and anti-carcinogenic effects  
40  
41 such as the induction of enzymes responsible for carcinogen detoxification, inhibition of carcinogen  
42  
43 activation activities and stimulating intracellular antioxidant defence (1-3). Observational studies  
44  
45 have investigated coffee and caffeine intake in relation to type 2 diabetes (4, 5), depression (6),  
46  
47 insomnia (7) as well as various cancers (8, 9), but the directions of association have been  
48  
49 inconsistent across diseases (10).  
50  
51

52  
53  
54 There are growing concerns regarding coffee consumption in relation to women's health. Epithelial  
55  
56 ovarian cancer (EOC) is a gynaecological malignancy with a high fatality rate. Approximately 151 900  
57  
58 women worldwide die of the disease annually (11). The high-grade serous histology is the most  
59  
60

1  
2  
3 common EOC subtype (12). Whilst many individual studies have found conflicting directions of  
4  
5 association with coffee consumption and EOC risk, subsequent meta-analysis studies found no  
6  
7 evidence for an association (13-18). A more recent Danish study (19) suggested that moderate  
8  
9 increase in daily caffeine intake (by one cup of coffee per day) might be protective against invasive  
10  
11 EOC. Inconsistencies observed in the literature may be due to the lack of compatibility of categorical  
12  
13 definitions (size of cup, content, caffeine intensity, method of brewing) and differences in definitions  
14  
15 for baseline groups (i.e. non-drinkers). Some studies further combined consumption of tea and  
16  
17 coffee to investigate caffeine intake specifically. However, more importantly, all studies to date  
18  
19 examining the link between coffee/caffeine and EOC risk are observational studies where bias due to  
20  
21 confounding may make it difficult to draw reliable conclusions (20). For example, we can  
22  
23 hypothesize that women diagnosed with EOC may have temporal nutritional awareness and develop  
24  
25 aversion to caffeinated beverages (such as coffee and cola), which may distort the true underlying  
26  
27 association in case-control studies. Since randomized trials examining coffee consumption in relation  
28  
29 to ovarian risk have not been conducted, to work around these potential biases, we can apply an  
30  
31 instrumental variable technique, Mendelian randomization (MR) (21) to draw causal inferences on  
32  
33 coffee consumption.  
34  
35  
36

37  
38 Twin studies have shown that coffee consumption has a substantial genetic component, with an  
39  
40 estimated heritability ranging from 0.37 – 0.77 (22-24). This suggests that coffee consumption may  
41  
42 be a suitable trait for MR studies. In this study we aim to refine the relationship between coffee and  
43  
44 EOC susceptibility. We hypothesize that genetic predisposition towards higher coffee intake is  
45  
46 inversely associated with i) overall EOC susceptibility and ii) high-grade serous EOC susceptibility,  
47  
48 and draw inference on causality via MR.  
49  
50  
51

## 52 53 54 55 56 **Methods:** 57 58 59 60

### Data source

Participants for this study were drawn from the Ovarian Cancer Association Consortium (OCAC). Genotyping was performed using the customised Infinium OncoArray-500K array (Illumina) (25) consisting of ~322 000 variants. OncoArray data were available for 59 115 samples across 71 study cohorts worldwide, of which 56 479 passed initial quality control protocols. Each individual was assigned values to indicate the proportion of European, African or Asian ancestry they inherited based on genetic makeup, using principal component analysis. These values sum up to 1 and are used to categorise the subjects into one of the intercontinental ancestry groups. Following that, imputation into the 1000 Genomes Project reference panel was carried out with pre-phasing using SHAPEIT and IMPUTE2 (26, 27). First-degree related individuals and duplicated samples (n=1 732) were removed. DNA samples from women of non-European ancestry were excluded for this study. The total sample size used in this study was 44 062 women of European ancestry (Table 1 shows a breakdown of the sample size by EOC histology). Baseline characteristics of our study samples from OCAC according to weight, age, smoking status and other potential confounders are summarised in Supplementary Table 1.

Genetic variants for the MR analyses were identified through an extensive review of published GWAS findings for coffee, tea and/or caffeine consumption (28-33). SNPs associated with coffee consumption (measured as cups/day) that were considered for use were rs1481012 in the *ABCG2* gene, rs6968554 in the *AHR* gene, rs2470893 in the *CYP1A2* gene, rs17685 in the *POR* gene and rs6265 in the *BDNF* gene. In our subsequent analysis, we investigated whether the association with coffee intake (in cups per day) onto ovarian cancer was driven mainly by genetic predisposition for altered caffeine intake. SNPs reported to show association with caffeine and considered for use here were rs6968865 from the *AHR* gene and rs2472297 from the *CYP1A2* gene. All of the SNPs investigated were either directly genotyped or imputed with high quality (info-score > 0.9). Although



1  
2  
3 these variants are different SNPs in AHR and CYP1A2, they are in high linkage-disequilibrium  
4  
5 ( $r^2=0.8$ ), see discussion for more detail. In order to ensure that our SNPs of interest are strong  
6  
7 instruments, we examined the statistical evidence in the literature for their association with coffee  
8  
9 and with caffeine consumption respectively. The variance on coffee consumption explained by a  
10  
11 particular SNP can be derived using  $r_{SNP}^2 = 2p(1 - p)\beta^2/\sigma^2$  where  $r_{SNP}^2$  refers to the variance  
12  
13 explained by the SNP,  $p$  refers to the MAF of the SNP,  $\beta$  is the measured magnitude of association  
14  
15 per effect allele and  $\sigma^2$  is the coffee trait variance. The variance explained by our SNP instruments  
16  
17 can hence be obtained by linearly summing up  $r_{SNP}^2$  across each independent SNP instrument. We  
18  
19 subsequently tested each SNP against potential confounders using publicly available GWAS datasets.  
20  
21 The possible confounders tested were age at menarche, measures of glycaemia, education  
22  
23 attainment, BMI, waist-hip ratio, body fat and smoking behaviour (supplementary table 3).  
24  
25  
26  
27  
28  
29  
30

### 31 **Causal Effect estimation**

32  
33 To perform MR we utilised a two sample statistical model to estimate the magnitude of association  
34  
35 between coffee consumption and ovarian cancer using summary statistics (34). We fitted an additive  
36  
37 model in SNPTTEST (35) to test for association between each SNP and ovarian cancer status. Within-  
38  
39 ancestry principal components (PC1-PC9) were fitted to remove potential bias arising from intra-  
40  
41 ethnic population difference. Additional covariates that might be confounders such as BMI, smoking  
42  
43 status and alcohol consumption were not available for all the genotyped OCAC participants and  
44  
45 hence were not included as covariates (although subject to the assumptions of MR, not including  
46  
47 these potential confounders as covariates will not bias our results) to maximize sample size. The  
48  
49 genomic control lambda value was computed using 483 972 SNPs genome-wide to assess the  
50  
51 possibility of population stratification biasing the association between allele frequencies and  
52  
53 phenotype.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 For both coffee and caffeine consumption we used the Wald-type ratio estimator (36) to combine  
4  
5 the SNP-estimates which uses the SNP-risk factor and SNP-cancer magnitude of association  
6  
7 estimates to calculate the aggregated causal effect. We estimated a causal OR (COR) for all ovarian  
8  
9 cancer and for the high grade serous subtype. High-grade serous was the only histological subtype  
10  
11 with sufficient numbers for sub-set analysis.  
12  
13  
14  
15  
16  
17

## 18 Results:

### 19 20 21 SNP Selection

22  
23  
24 We shortlisted a total of 4 independent SNPs (rs1481012, rs6968554, rs2470893, rs17685) as proxies  
25  
26 for genetically determined coffee consumption behaviour (31). For the analysis on caffeine, we used  
27  
28 2 SNPs (rs6968865,rs2472297) (33) as genetic proxies for total caffeine consumption per day (in  
29  
30 mg). Each of these SNPs is robustly associated with p-values less than  $p < 5 \times 10^{-8}$  for coffee  
31  
32 consumption in the original coffee GWAS. Due to the smaller sample size in the published analysis  
33  
34 for caffeine consumption, the published p-values for the effects of rs6968865 and rs2472297 on  
35  
36 caffeine consumption were not as strong as those for the SNP-coffee associations but both of the  
37  
38 SNPs combined associate with caffeine consumption with a p-value= $3.74 \times 10^{-14}$  (33), with its  
39  
40 direction of association verified in an Australian sample (Supplementary A1). Each of the SNPs thus  
41  
42 satisfies the strong MR instrument criterion ( $F \gg 10$ ).  
43  
44  
45  
46  
47

48 In our pleiotropy assessment, the SNP rs6265 in the *BDNF* gene was found to have pleiotropic effects  
49  
50 on other traits of relevance to ovarian cancer (BMI and age of menarche, supplementary material)  
51  
52 so it was excluded from our analyses. After removing BDNF, the 4 coffee SNPs combined explain  
53  
54 about ~1.2% of the variation in coffee intake (31), whereas the 2 SNPs combined for our MR caffeine  
55  
56 study explain about ~1.3% of the variation in caffeine intake (33). We also tested the association  
57  
58  
59  
60

1  
2  
3 between established ovarian cancer risk factors (oral contraceptive use, estrogen use, parity) and  
4  
5 our SNPs of interest. The results of our pleiotropy assessment are available in Supplementary Table  
6  
7 3(publicly available GWAS) and Supplementary Table 4 (OCAC dataset). In brief, no associations were  
8  
9 found above chance level and we conclude that the assumptions of no-pleiotropy is not violated. In  
10  
11 particular, coffee consumption and cigarette consumption are correlated in some populations but  
12  
13 our chosen SNPs are not associated with smoking (Supplementary Table 3).  
14  
15  
16  
17  
18

### 19 **Instrumental variable analysis**

20  
21 The SNP-cancer association results for each genetic instrument used are available in Supplementary  
22  
23 Table 2. We estimated the causal odds ratio associated with a genetically predicted one cup per day  
24  
25 change in coffee consumption. For all EOC cases the COR for consuming one additional cup of coffee  
26  
27 per day was 0.92 (95% confidence interval, CI: 0.79, 1.06). For high-grade serous EOC, the COR was  
28  
29 0.90 (95% CI: 0.73, 1.10). We also performed an additional analysis to investigate caffeine  
30  
31 consumption, with the COR scaled in terms of an 80mg increase (the approximate caffeine content  
32  
33 in a conventional cup of coffee). The COR for consuming an additional 80mg of caffeine was 1.01 (CI:  
34  
35 0.92, 1.11) for all EOC cases and 0.90 (CI: 0.73, 1.10) for high-grade serous. The CORs derived from  
36  
37 individual SNP instruments are shown in Figure 1 for coffee consumption; and Figure 2 for caffeine  
38  
39 intake.  
40  
41  
42  
43  
44  
45

### 46 **Population Stratification and confounding**

47  
48 Due to the missing covariate data on some OCAC participants (see Supplementary Table 1), the  
49  
50 analyses were performed by only fitting the first 9 genetic (ancestral) principal components as  
51  
52 covariates. In a sensitivity analysis using participants with confounder data available (n~11 400),  
53  
54 adjustment for potential confounders (age of menarche, education level, number of pregnancies,  
55  
56  
57  
58  
59  
60

1  
2  
3 oral contraceptive use, estrogen use, smoking and BMI) did not change the magnitude of the SNP-  
4  
5 disease associations (See Supplementary Table 6). The genomic control lambda was 1.076  
6  
7 ( $\lambda_{1000} = 1.007$ , LD-score intercept=1.032) demonstrating that there is little evidence for inflation of  
8  
9 the genome-wide association statistics due to population stratification. Plots of the ancestral  
10  
11 principal components (PC1 against PC2) between cases and controls indicate that the cases and  
12  
13 controls are homogeneous (See Supplementary Figure 1 and 2).  
14  
15  
16  
17  
18

## 19 **Discussion:**

20  
21  
22 In our study sample of 44 062 European participants from OCAC, we found no evidence suggestive of  
23  
24 a large causal association between (genetically predicted) coffee consumption and overall EOC risk  
25  
26 nor on high-grade serous EOC. Similarly, our findings consistently suggest no causal link between  
27  
28 caffeine intake and EOC susceptibility.  
29  
30  
31

## 32 **Research in context**

33  
34  
35 Most epidemiological studies in the past investigated the association of EOC with coffee  
36  
37 consumption by assessing the difference in EOC risk among non-coffee drinkers and strong coffee  
38  
39 drinkers. Consumption of > 3 cups of coffee per day was used as a benchmark to indicate strong  
40  
41 coffee drinking behaviour. To compare our results, we rescaled findings from these observational  
42  
43 studies to reflect an averaged moderate change in daily coffee consumption (1 cup of coffee per  
44  
45 day) using Equation 1 in Supplementary material. The resultant estimates from our study were  
46  
47 broadly compatible with results of previous meta-analyses (Figure 3).  
48  
49  
50

51  
52 Although some individual observational studies have found associations between coffee  
53  
54 consumption and risk of EOC, meta-analyses have found no evidence to show that coffee  
55  
56 consumption protects against EOC (13). However, a common criticism of observational studies is  
57  
58 inconsistency in the definition of categorised consumption (i.e. different studies adopt different  
59  
60

1  
2  
3 definitions of heavy drinkers) and the variability in types of coffee beverages, which may differ  
4  
5 strongly in terms of nutritional content (most importantly, caffeine). These systematic differences  
6  
7 can make the interpretation of meta-analysed findings difficult. Moreover, it is difficult to rule out  
8  
9 the potential effects of selection bias in case-control studies and of unmeasured or uncontrolled  
10  
11 confounding in observational studies in general. In contrast, here we use genetically predicted coffee  
12  
13 intake to provide more uniform estimates of coffee consumption in a large sample size (coffee  
14  
15 GWAS (31),  $n > 80\,000$ ). Our 2-sample MR design allows us to investigate the underlying association  
16  
17 without the issue of potential confounders such as education level, alcohol use and smoking  
18  
19 behaviour, which was established by earlier studies to be strongly correlated to coffee consumption.  
20  
21 In our pleiotropy assessment, the SNP instruments we employ are not associated with these  
22  
23 potential confounders (Supplementary table 3).  
24  
25  
26

27  
28 Even though the MR analyses were performed separately for coffee consumption and caffeine  
29  
30 intake with independent SNPs within each study, the inference we draw from these findings are not  
31  
32 independent. This is due to the fact that, for each study the most important single SNPs (rs2470893  
33  
34 in *CYP1A2* which explains ~0.5% of the variance in coffee consumption (31) and rs2472297 in  
35  
36 *CYP1A2* which explains ~0.8% of the variance in caffeine consumption (33)) are in high linkage  
37  
38 disequilibrium ( $r^2 = 0.7$  between the two SNPs). Hence, the effect of those SNPs (rs2470893,  
39  
40 rs2472297) on coffee and caffeine consumption may not be separable (i.e. *CYP1A2* is involved in  
41  
42 metabolizing common bioactive compounds in coffee). The same applies for SNP rs6968865 and  
43  
44 rs6968554 in *AHR*.  
45  
46  
47

48  
49 Previous studies have highlighted a potential role of caffeine in inducing p53-dependent (tumour  
50  
51 suppression gene) apoptosis (37). Since *TP53* mutations are found in almost all high-grade serous  
52  
53 EOC (38), an analysis of high-grade serous alone was of particular interest. However in our study,  
54  
55 coffee and caffeine intake did not appear to be associated with any risk of high-grade serous  
56  
57  
58  
59  
60

1  
2  
3 carcinoma among Europeans.  
4  
5  
6  
7

### 8 **Strengths and limitations**

9

10 One of the strength of our study is that participants used in our analyses were all of European  
11 ancestry, limiting potential bias due to population heterogeneity. Furthermore, the use of ancestral  
12 principal components to define ethnicity also prevents heritage-reporting errors (i.e. ethnicity was  
13 determined based on SNP profiles, as summarised by ancestry principal components to avoid self-  
14 reporting biases). In our MR study, the use of GWAS findings to predict coffee/caffeine consumption  
15 rather than relying on self-reports of consumption should remove misclassification biases that can  
16 plague self-reported studies and contribute to statistical heterogeneity in meta-analyses of  
17 observational studies. Since coffee consumption generally stabilizes during adulthood, our 2-sample  
18 MR approach is protected by potential biases due to apparent age differences between the SNP-  
19 coffee samples and the OCAC samples. In other words, the estimated SNP-coffee association during  
20 adulthood remain a robust genetic predisposition to lifetime coffee intake behaviour.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 For our MR to infer about causality, several MR assumptions have to be met. Firstly, the instruments  
38 (SNPs) used here were robustly associated (with  $F >> 10$ ) to coffee and caffeine intake respectively.  
39  
40 Secondly, the SNPs used in this study showed no evidence for any pleiotropic effects that may  
41 confound the association with EOC susceptibility. The third MR assumption, that the genetic variants  
42 used in our study only influence EOC susceptibility through mediating coffee consumption, can be  
43 difficult to test directly. However, previous studies have examined the role of *CYP1A1*, *CYP1A2* and  
44 *AHR* in detail (28, 29, 32, 39). In each case, a SNP in or near the gene has been implicated by GWAS  
45 and we assume that the action of the SNP on coffee consumption is via the specified gene. Taking  
46 each in turn, *CYP1A2* encodes the primary enzyme that metabolises caffeine in the liver, while  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
*CYP1A1* encodes protein that metabolises polycyclic aromatic hydrocarbons, which are more

1  
2  
3 commonly found in coffee beans. The *AHR* gene is known to induce both *CYP1A1* and *CYP1A2* via a  
4 DNA binding mechanism (29) and is also responsible in detection of toxic chemicals (39). Despite  
5 coffee intake being strongly correlated with smoking, our pleiotropy assessment indicated that none  
6 of the SNPs appear to be associated (Bonferroni corrected p-value > 0.05) with smoking behaviours.  
7  
8 Moreover, the lack of a main effect of the SNPs on smoking makes a coffee-smoking interaction less  
9 likely - Thus, it seems very improbable that these SNPs directly influence ovarian cancer through  
10 other independent biological processes.  
11  
12

13  
14 Although we found no evidence supportive of an association between the SNPs used and common  
15 risk factors for EOC (40, 41)(e.g. smoking, oral contraceptive use, parity, etc.), it is hard to rule out  
16 directly possibilities of residual pleiotropy. However, suppose that a SNP has a strong pleiotropic  
17 effect which biases our results - for us to observe the null causal odds ratio we find here, the other  
18 SNPs (or some combination of SNPs) must act pleiotropically in the opposite direction and with  
19 similar magnitude to the first SNP. Since this is unlikely, it is unlikely that pleiotropic effects have a  
20 considerable influence on our non-causality conclusion.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 There are some limitations that should also be considered in our analyses. Firstly, our study was  
38 performed using only European ancestry women and our findings may not generalize to other  
39 populations. Even though our SNPs are strong instruments, taken from large GWAS studies, all our  
40 SNPs combined only account for a relatively small proportion of variation (~1.2%) in coffee  
41 consumption (cups per day). The variance explained directly influences the precision of our  
42 estimates and with a larger proportion of variance explained (or a larger sample size), the confidence  
43 interval on our causal odds ratio would be smaller. However, for both all histologies and high grade  
44 serous histology alone, the confidence intervals from our study are small enough to exclude all but  
45 small (<10%) true effects of coffee consumption on cancer risk. Our study does not have good power  
46 for the individual subtypes other than high grade serous and we have insufficient power to perform  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 stratified analyses (e.g. based on groups with particular smoking or BMI status).  
4  
5

6  
7 The difference in coffee consumption as quantified in our MR analysis can be hard to interpret. In  
8  
9 our analysis, CORs are calculated based on one additional cup of coffee per day averaging across all  
10  
11 possible quantities of coffee consumption among regular coffee drinkers (including non-drinkers).  
12  
13 This made it difficult to compare our estimates reliably with those from studies that investigated  
14  
15 extreme ends of the trait distribution (heavy coffee drinking (>5 cups) and/or coffee drinkers to non-  
16  
17 drinkers). Here, it is difficult for our study to completely rule out previous findings that showed  
18  
19 positive associations of EOC when comparing very heavy coffee-drinkers to other categories (13).  
20  
21 That is, our findings only infer that moderate differences in coffee consumption (averaging over the  
22  
23 entire trait distribution) do not influence risk of EOC as the MR framework assumes that modifiable  
24  
25 exposures linearly affect the underlying risk factor; which might be violated if the outcome to  
26  
27 exposure relationship is non-linear (follows a J-shaped curve).  
28  
29  
30

31  
32 An additional consideration is how to handle non-coffee drinkers. For caffeine this is not an issue  
33  
34 because non-users are included in the SNP association studies. For coffee consumption, in our main  
35  
36 analysis, we focus on “cups per day” coffee consumption. However, the GWASs to date on “cups per  
37  
38 day” in coffee consumers also found (31) that the same SNPs were also strongly associated with  
39  
40 drinking status (“high” versus “low/no” coffee consumption). Hence our findings in support of non-  
41  
42 causality of “cups per day” probably extend to alternative definitions such as “high” versus “low/no”  
43  
44 status.  
45  
46  
47  
48

49  
50 We found no evidence indicative of a strong association between EOC risk and genetically predicted  
51  
52 coffee or caffeine levels. However, our estimates were not statistically inconsistent with earlier  
53  
54 observational studies and we were unable to rule out small protective associations. Our MR based  
55  
56 results are more readily interpretable than previous observational studies because they are unlikely  
57  
58  
59  
60



1  
2  
3 to be adversely affected by confounding biases which can invalidate the conclusions from  
4  
5 observational studies.  
6  
7  
8  
9

## 10 11 **Funding**

12  
13  
14 This work was supported by The COGS project which is funded through a European Commission's  
15  
16 Seventh Framework Programme Grant (agreement number 223175 HEALTH F2 2009-223175); the  
17  
18 Genetic Associations and Mechanisms in Oncology (GAME-ON): A NCI Cancer Post-GWAS Initiative  
19  
20 (U19-CA148112); the Ovarian Cancer Association Consortium is supported by a grant from the  
21  
22 Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek  
23  
24  
25 Smith (PPD/RPCI.07). Funding of the constituent studies was provided by the California Cancer  
26  
27  
28 Research Program (00-01389V-20170, N01-CN25403, 2II0200); the Canadian Institutes of Health  
29  
30  
31 Research (MOP-86727); Cancer Australia; Cancer Council Victoria; Cancer Council Queensland;  
32  
33  
34  
35 Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer  
36  
37  
38 Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK  
39  
40  
41 (C490/A6187, C490/A10119, C490/A10124); the Danish Cancer Society (94-222-52); the ELAN  
42  
43  
44 Program of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Central  
45  
46  
47 Hospital Research Fund; Helse Vest; the Norwegian Cancer Society; the Norwegian Research Council;  
48  
49  
50 the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; the L & S Milken Foundation;  
51  
52  
53 the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell  
54  
55  
56 Park Cancer Institute Alliance Foundation; Breast Cancer Now, the Institute of Cancer Research, NHS  
57  
58  
59 funding to the Royal Marsden/ICR NIHR Biomedical Research Centre; the US National Cancer  
60

1  
2  
3 Institute (K07-CA095666, K07-CA80668, K07-CA143047, K22-CA138563, N01-CN55424, N01-  
4  
5 PC67001, N01-PC067010, N01-PC035137, P01-CA017054, P01-CA087696, P30-CA072720, P30-  
6  
7 CA15083, P30-CA008748, P50-CA159981, P50-CA105009, P50-CA136393, R01-CA149429, R01-  
8  
9 CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01-  
10  
11 CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA063678, R01-CA063682, R01-  
12  
13 CA067262, R01-CA071766, R01-CA074850, R01-CA080978, R01-CA083918, R01-CA087538, R01-  
14  
15 CA092044, R01-CA095023, R01-CA122443, R01-CA112523, R01-CA114343, R01-CA126841, R01-  
16  
17 CA136924, R03-CA113148, R03-CA115195, U01-CA069417, U01-CA071966, UM1-CA186107, UM1-  
18  
19 CA176726 and Intramural research funds); the NIH/National Center for Research Resources/General  
20  
21 Clinical Research Center (MO1-RR000056); the US Army Medical Research and Material Command  
22  
23 (DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669, W81XWH-07-0449, W81XWH-10-1-  
24  
25 02802); the US Public Health Service (PSA-042205); the National Health and Medical Research  
26  
27 Council of Australia ( 199600 and 400281); the German Federal Ministry of Education and Research  
28  
29 of Germany Programme of Clinical Biomedical Research (01GB 9401); the State of Baden-  
30  
31 Wurttemberg through Medical Faculty of the University of Ulm (P.685); the German Cancer Research  
32  
33 Center; the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B.  
34  
35 Andersen Foundation; the Lon V. Smith Foundation (LVS-39420); the Oak Foundation; Eve Appeal;  
36  
37 the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National  
38  
39 Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial  
40  
41 College London, University College Hospital 'Womens' Health Theme' and the Royal Marsden  
42  
43 Hospital; and Work Safe BC 14.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Investigator-specific funding: JS and GC thank the University of Queensland and QIMR Berghofer  
7  
8  
9 Medical Research Institute for scholarship support. YL was supported by the NHMRC Early Career  
10  
11  
12 Fellowship. GCT, REN and PMW are supported by the National Health and Medical Research Council.  
13  
14  
15 SM acknowledges funding support from an Australian Research Council Future Fellowship.  
16  
17  
18  
19  
20

## 21 **Acknowledgements**

22  
23  
24 We acknowledge with appreciation all the individuals who participated in the OCAC studies, and the  
25  
26  
27 many hospital directors and staff, gynaecologists, general practitioners and pathology services who  
28  
29  
30 provided assistance with confirmation of diagnoses, and the many research assistants and  
31  
32  
33 interviewers for assistance with the studies. For the OCAC studies, we thank: D.Bowtell, A. deFazio,  
34  
35  
36 D. Gertig, A. Green, P. Parsons, N. Hayward, and D. Whiteman (AUS); G. Peuteman, T. Van Brussel  
37  
38  
39 and D. Smeets (BEL); L. Gacucova (HMO); P. Schurmann, F. Kramer, W. Zheng, T. W. Park, Simon, K.  
40  
41  
42 Beer-Grondke and D. Schmidt (HJO); S. Windebank, C. Hilker and J. Vollenweider (MAY); the state  
43  
44  
45 cancer registries of AL, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KY, LA, ME,  
46  
47  
48 MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA and WYL(NHS); L. Paddock, M.  
49  
50  
51 King, L. Rodriguez-Rodriguez, A. Samoila and Y. Bensman (NJO); M. Sherman, A. Hutchinson, N.  
52  
53  
54 Szeszenia-Dabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao and M. Stagner (POL); C. Luccarini,  
55  
56  
57 P. Harrington the SEARCH team and ECRIC (SEA); I. Jacobs, M. Widschwendter, E. Wozniak, N.  
58  
59  
60

Balogun, A. Ryan, C. Karpinskyj and J. Ford (UKO); Carole Pye (UKR); A. Amin Al Olama, J. Dennis, E.

Dicks, K. Michilaidou and K. Kuchenbaker (COGS).

## Reference

1. Huber WW, Rossmannith W, Grusch M, Haslinger E, Prustomersky S, Peter-Vorosmarty B, et al. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association*. 2008;46(4):1230-8.
2. Huber WW, Scharf G, Nagel G, Prustomersky S, Schulte-Hermann R, Kaina B. Coffee and its chemopreventive components Kahweol and Cafestol increase the activity of O6-methylguanine-DNA methyltransferase in rat liver--comparison with phase II xenobiotic metabolism. *Mutation research*. 2003;522(1-2):57-68.
3. Boettler U, Volz N, Teller N, Haupt LM, Bakuradze T, Eisenbrand G, et al. Induction of antioxidative Nrf2 gene transcription by coffee in humans: depending on genotype? *Molecular biology reports*. 2012;39(6):7155-62.
4. Jiang X, Zhang D, Jiang W. Coffee and caffeine intake and incidence of type 2 diabetes mellitus: a meta-analysis of prospective studies. *European journal of nutrition*. 2014;53(1):25-38.
5. Lee JK, Kim K, Ahn Y, Yang M, Lee JE. Habitual coffee intake, genetic polymorphisms, and type 2 diabetes. *European journal of endocrinology / European Federation of Endocrine Societies*. 2015;172(5):595-601.
6. Lucas M, Mirzaei F, Pan A, Okereke OI, Willett WC, O'Reilly EJ, et al. Coffee, caffeine, and risk of depression among women. *Archives of internal medicine*. 2011;171(17):1571-8.
7. Skarupke C, Schlack R, Lange K, Goerke M, Dueck A, Thome J, et al. Insomnia complaints and substance use in German adolescents: did we underestimate the role of coffee consumption? Results of the KiGGS study. *Journal of neural transmission*. 2015.
8. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause-specific mortality. *The New England journal of medicine*. 2012;366(20):1891-904.
9. Crippa A, Discacciati A, Larsson SC, Wolk A, Orsini N. Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. *American journal of epidemiology*. 2014;180(8):763-75.
10. Schoenfeld JD, Ioannidis JP. Is everything we eat associated with cancer? A systematic cookbook review. *Am J Clin Nutr*. 2013;97(1):127-34.
11. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA: a cancer journal for clinicians*. 2015;65(2):87-108.
12. Koti M, Siu A, Clement I, Bidarimath M, Turashvili G, Edwards A, et al. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. *British journal of cancer*. 2015;112(7):1215-22.
13. Braem MG, Onland-Moret NC, Schouten LJ, Tjonneland A, Hansen L, Dahm CC, et al. Coffee and tea consumption and the risk of ovarian cancer: a prospective cohort study and updated meta-analysis. *Am J Clin Nutr*. 2012;95(5):1172-81.
14. Steevens J, Schouten LJ, Verhage BA, Goldbohm RA, van den Brandt PA. Tea and coffee drinking and ovarian cancer risk: results from the Netherlands Cohort Study and a meta-analysis. *British journal of cancer*. 2007;97(9):1291-4.
15. Song YJ, Kristal AR, Wicklund KG, Cushing-Haugen KL, Rossing MA. Coffee, tea, colas, and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2008;17(3):712-6.

16. Lueth NA, Anderson KE, Harnack LJ, Fulkerson JA, Robien K. Coffee and caffeine intake and the risk of ovarian cancer: the Iowa Women's Health Study. *Cancer causes & control : CCC*. 2008;19(10):1365-72.
17. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Intake of coffee and tea and risk of ovarian cancer: a prospective cohort study. *Nutrition and cancer*. 2007;58(1):22-7.
18. Goodman MT, Tung KH, McDuffie K, Wilkens LR, Donlon TA. Association of caffeine intake and CYP1A2 genotype with ovarian cancer. *Nutrition and cancer*. 2003;46(1):23-9.
19. Gosvig CF, Kjaer SK, Blaakaer J, Hogdall E, Hogdall C, Jensen A. Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. *Acta oncologica*. 2015;54(8):1144-51.
20. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. *Bmj*. 1998;316(7125):140-4.
21. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Stat Med*. 2008;27(8):1133-63.
22. Vink JM, Staphorsius AS, Boomsma DI. A genetic analysis of coffee consumption in a sample of Dutch twins. *Twin research and human genetics : the official journal of the International Society for Twin Studies*. 2009;12(2):127-31.
23. Laitala VS, Kaprio J, Silventoinen K. Genetics of coffee consumption and its stability. *Addiction*. 2008;103(12):2054-61.
24. Luciano M, Kirk KM, Heath AC, Martin NG. The genetics of tea and coffee drinking and preference for source of caffeine in a large community sample of Australian twins. *Addiction*. 2005;100(10):1510-7.
25. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature genetics*. 2017.
26. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nature genetics*. 2012;44(8):955-9.
27. O'Connell J, Gurdasani D, Delaneau O, Pirastu N, Ulivi S, Cocca M, et al. A general approach for haplotype phasing across the full spectrum of relatedness. *PLoS genetics*. 2014;10(4):e1004234.
28. Josse AR, Da Costa LA, Campos H, El-Sohemy A. Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. *Am J Clin Nutr*. 2012;96(3):665-71.
29. Amin N, Byrne E, Johnson J, Chenevix-Trench G, Walter S, Nolte IM, et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. *Molecular psychiatry*. 2012;17(11):1116-29.
30. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. *PLoS genetics*. 2011;7(4):e1002033.
31. Coffee, Caffeine Genetics C, Cornelis MC, Byrne EM, Esko T, Nalls MA, et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. *Molecular psychiatry*. 2015;20(5):647-56.
32. Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KK, et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. *Human molecular genetics*. 2011;20(10):2071-7.
33. McMahon G, Taylor AE, Davey Smith G, Munafo MR. Phenotype refinement strengthens the association of AHR and CYP1A1 genotype with caffeine consumption. *PloS one*. 2014;9(7):e103448.
34. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG, Consortium E-I. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *European journal of epidemiology*. 2015;30(7):543-52.

- 1
- 2
- 3 35. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-
- 4 wide association studies by imputation of genotypes. *Nature genetics*. 2007;39(7):906-13.
- 5 36. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
- 6 genetic variants using summarized data. *Genetic epidemiology*. 2013;37(7):658-65.
- 7 37. He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z. Induction of apoptosis by caffeine is
- 8 mediated by the p53, Bax, and caspase 3 pathways. *Cancer research*. 2003;63(15):4396-401.
- 9 38. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma.
- 10 *Nature*. 2011;474(7353):609-15.
- 11 39. Lensu S, Tuomisto JT, Tuomisto J, Viluksela M, Niittynen M, Pohjanvirta R. Immediate and
- 12 highly sensitive aversion response to a novel food item linked to AH receptor stimulation. *Toxicology*
- 13 *letters*. 2011;203(3):252-7.
- 14 40. Kurman RJ, Shih le M. Pathogenesis of ovarian cancer: lessons from morphology and
- 15 molecular biology and their clinical implications. *International journal of gynecological pathology :*
- 16 *official journal of the International Society of Gynecological Pathologists*. 2008;27(2):151-60.
- 17 41. Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer:
- 18 an overview with emphasis on hormonal factors. *J Toxicol Environ Health B Crit Rev*. 2008;11(3-
- 19 4):301-21.
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

**Table 1 : Distribution of EOC cases among European participants in OCAC.**

<b>Nature/Subtype</b>	<b>European Cases</b>
<b>Invasive</b>	17,779
<b>All serous<sup>‡</sup></b>	11,213
<b>Endometrioid</b>	2,199
<b>Clearcell</b>	1,121
<b>Mucinous</b>	1,125
<b>All mucinous<sup>‡</sup></b>	2,023
<b>High-grade serous</b>	7,488
<b>Low-grade serous</b>	880
<b>All EOC cases<sup>‡</sup></b>	20,683

<sup>‡</sup>Including unclassified and unknown serous/mucinous ovarian tumours.

Note: A complete breakdown of the EOC cases by each participating study is provided in Supplementary Material.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1A. Instrumental variable estimate for coffee consumption on EOC susceptibility.

237x159mm (72 x 72 DPI)

Preview Only



**Estimated effect of 1 additional cup per day of  
coffee consumption on high-grade serous EOC risk**




Figure 1B. Instrumental variable for coffee consumption on high-grade serous EOC susceptibility.

242x159mm (72 x 72 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Estimated effect of additional 80mg caffeine intake per day on all EOC risk**




Figure 2A. Instrumental variable estimate for caffeine intake on EOC susceptibility.

242x159mm (72 x 72 DPI)

Preprint Only

**Estimated effect of additional 80mg caffeine  
intake per day on high-grade serous EOC risk**




Figure 2B. Instrumental variable estimate for caffeine intake on high-grade serous EOC susceptibility.

242x159mm (72 x 72 DPI)

Pre-Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Comparison to previous studies on association of coffee consumption with EOC susceptibility**




Figure 3. Comparison of Instrumental variable findings with observational studies.

242x159mm (72 x 72 DPI)

Pre-proof Only